ProCE Banner Activity

JADE COMPARE Analysis: Defining the Depth and Rapidity of Response of Abrocitinib and Dupilumab in Patients With Moderate to Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Study suggests that treatment with abrocitinib 200 mg QD results in a greater and more rapid response vs dupilumab, as assessed using stringent endpoints.

Released: June 15, 2021

Expiration: June 14, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Incyte Corporation